Galectin Therapeutics (GALT) Income from Continuing Operations (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Income from Continuing Operations of 6029000.0 for Q1 2026, up 37.24% year-over-year from 4393125.54 in Q1 2025, and up 43.17% quarter-over-quarter from 10608000.0 in Q4 2025.
Powered by 
Analysis
Galectin Therapeutics (GALT) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 6029000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 37.24% year-over-year to 6029000.0; the TTM figure through Mar 2026 stood at 29041000.0 (up 42.42% YoY), while the FY2025 annual figure was 115625000.0, up 12.69% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 6029000.0, up from 10608000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 5979000.0 in Q3 2025, with the low at 17884000.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 9939000.0 (2023), against an average of 9991764.71.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations plunged 87.42% in 2024, then surged 48.52% in 2025.
- Galectin Therapeutics' Income from Continuing Operations stood at 11486000.0 in 2022, then rose by 16.92% to 9542000.0 in 2023, then slumped by 87.42% to 17884000.0 in 2024, then soared by 40.68% to 10608000.0 in 2025, then soared by 43.17% to 6029000.0 in 2026.
- Business Quant data shows GALT's Income from Continuing Operations at 6029000.0 in Q1 2026, 10608000.0 in Q4 2025, and 5979000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Galectin Therapeutics | 304.34 Mn | 304.34 Mn | - | -5.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.96 Mn |
| Mar 31, 2026 | -6.03 Mn |
| Dec 31, 2025 | -5.28 Mn |
| Sep 30, 2025 | -5.98 Mn |
| Jun 30, 2025 | -6.43 Mn |
| Mar 31, 2025 | -9.61 Mn |
| Dec 31, 2024 | -14.07 Mn |
| Sep 30, 2024 | -10.47 Mn |
| Jun 30, 2024 | -12.48 Mn |
| Mar 31, 2024 | -10.62 Mn |
| Dec 31, 2023 | -10.33 Mn |
| Sep 30, 2023 | -9.94 Mn |
| Jun 30, 2023 | -9.60 Mn |
| Mar 31, 2023 | -10.76 Mn |
| Dec 31, 2022 | -10.91 Mn |
| Sep 30, 2022 | -8.37 Mn |
| Jun 30, 2022 | -9.90 Mn |
| Mar 31, 2022 | -10.16 Mn |
| Dec 31, 2021 | -7.70 Mn |
| Sep 30, 2021 | -8.35 Mn |